Nectar Lifesciences Ltd

Stage 1 · Basing · week 5

As of 16 Oct 2026, Nectar Lifesciences is in Stage 1 — basing, not yet in an uptrend, in week 5 (since 17 Sep 2026). It closed at ₹10.54, 52.6% below its 52-week high and below its 200-day average, which is falling. In Health Care, 40.6% of stocks are in Stage 2.

Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. More about the company

₹10.5
+4.98% today
₹205 Cr · Micro cap
Market Neutral — FadingHealth Care 40.6% in Stage 2-7.4 pts / 20dPharmaceuticals 50.4%-2.5 pts

Pro read

Pro

Our read

Basing — not in an uptrend yet

Setup score

—

Momentum

Steady

Edge

—

Is NECLIFE early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-52.6%
₹9.3 lo₹22.3 hi
52.6% below 52W high
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 5
1w13w26w
Week 5 — early base, needs time
How long this stock has been basing. Longer bases can produce stronger breakouts — but don't anticipate, wait for the breakout.
vs 200 DMA
-14.0%
200 DMA: ₹12.3 · sloping down
Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.
Rel Volume
0.77x
vs 50-day avg
Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.
Trend Health
↓
MA20 rolling over · -6.0% vs MA50 -0.4%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-3.3%
3M
-2.9%
6M
-15.1%
YTD
-52.4%
1Y
-26.3%
Sector
Health Care
↓ Peaking
Stage 2%
40.6%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
Sector has 67 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
50.4%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Industry has 57 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Stage Cycle Timeline2023-07-20 → 2026-10-16
S2 18w
S3 16w
S4 39w
S4 15w
2023-07-202026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 2w → S2 12w → S3 5w → S2 18w → S3 16w → S4 5w → S1 1w → S2 10w → S3 7w → S2 6w → S3 1w → S4 39w → S1 10w → S4 15w → S1 7w → S4 9w → S1 4w current
Total tracked: 169 weeks across 17 stage runs.
Scan Membership
Breakout Watch
Latest: 2025-01-07
2 appearances in last 60 days. First seen: 2024-09-09.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding — staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-16S1
Wk 5 · Vol 0.77x
2026-10-15S1
Wk 4 · Vol 0.43x
2026-10-14S1
Wk 4 · Vol 0.25x
2026-10-13S1
Wk 4 · Vol 0.46x
2026-10-12S1
Wk 4 · Vol 0.61x
2026-10-09S1
Wk 4 · Vol 0.91x
2026-10-08S1
Wk 3 · Vol 0.52x
2026-10-07S1
Wk 3 · Vol 0.60x
2026-10-06S1
Wk 3 · Vol 1.54x
2026-10-05S1
Wk 3 · Vol 1.42x
2026-10-01S1
Wk 3 · Vol 0.66x
2026-09-30S1
Wk 2 · Vol 0.60x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹11.1
200 DMA
₹12.3
52W High
₹22.3
52W Low
₹9.3
5D Low
₹10
Resistance levels (recent highs)
20d High
₹11.1
60d High
₹13.1
120d High
₹14.4
250d High
₹22.3
Next resistance
+4.9%
to 20d High
Ask the Market AI about NECLIFEAsk →
Earnings Growth (YoY)
+82.9%
Revenue —
About this companyHealth Care· Pharmaceuticals

Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also provides contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company offers menthol and pearl capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.